Specially, there is no significant difference of the biochemical indicators to assess the functions of the liver (such as alanine aminotransferase (ALT), aspartic transaminase (AST), and alkaline phosphatase (ALP) and kidney (such as urea, and creatinine) between control and hymecromone-treated groups (Supplementary Fig. 6), indicating that the current administration of hymecromone did not injury the functions of the liver and kidney in COVID-19 patients. The gene discussed is GPT; the disease is COVID-19.